Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 1373 results for social care

  1. Zuranolone for treating postnatal depression [ID6431]

    In development Reference number: GID-TA11356 Expected publication date: TBC

  2. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  3. Inflammatory bowel disease (QS81)

    This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  4. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

  5. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  21 January 2026

  6. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development Reference number: GID-TA11662 Expected publication date:  11 February 2026

  7. Postnatal care (QS37)

    This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.

  8. Depression in children and young people (QS48)

    This quality standard covers diagnosing and managing depression in children and young people (aged 5 to 18). It describes high-quality care in priority areas for improvement.

  9. Transient loss of consciousness ('blackouts') in over 16s (CG109)

    This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.

  10. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.

  11. Public health advisory committees

    The standing committees were responsible for the development of our public health guidance.

  12. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

  13. Atopic eczema in under 12s (QS44)

    This quality standard covers diagnosing and managing atopic eczema in children under 12. It describes high-quality care in priority areas for improvement.

  14. Board members

    Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.

  15. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (NG237)

    This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.